Oh, the problem is "hear" is it?
No one actually takes serious note of your comments. You do not present yourself as a savvy investor. I can't take you seriously and neither should anyone else who truly cares about making well informed investment decisions.
Fully funded phase 2 trial NHMRC, GvHD Phase 2 trial with Fujifilm, Fidelity as one of our major shareholders, all the cells we will ever need from one-donor, commercial scale expandability, higher efficacy at a lower dose... the list goes on and on VS Basza & Co and a first generation MSC technology that has burned through more cash that Donald Trump has with fake tan...... the devil is in the detail.
Temcell 8-12 infusions vs CYP-001 2-3 infusions for a complete response. Apply that on global scale and you have enormous cost savings no issues batch to batch cell variability, as is the case with first-generation bone-marrow derived cells.
2020 - A Year Full Of Potentials, page-176
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $39.74M | |||
| Open | High | Low | Value | Volume |
| 22.0¢ | 22.5¢ | 22.0¢ | $29.06K | 131.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 951 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 10000 | 1 |
View Market Depth
| Last trade - 15.59pm 08/11/2024 (20 minute delay) ? |
| CYP (ASX) Chart |